RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF

The disclosure relates to rifamycin analog compounds, intermediates and precursors thereof, and pharmaceutical compositions capable of inhibiting bacterial growth (e.g., S. aureus growth) and treating bacterial infections (e.g., S. aureus infections). The disclosure further relates to antibody-drug conjugates of rifamycin analog compounds and antibodies, for example, antibodies specific for infectious disease-related targets such as membrane glycoprotein receptor (MSR1), wall teichoic acids (WTA) or Protein A, and methods of use thereof to inhibit bacterial growth and treat bacterial infections. 本公开内容涉及利福霉素类似物化合物、其中间体和前体，以及能够抑制细菌生长(例如金黄色葡萄球菌生长)并治疗细菌感染(例如金黄色葡萄球菌感染)的药物组合物。本公开内容还涉及利福霉素类似物化合物与抗体的抗体-药物缀合物以及该抗体-药物缀合物用于抑制细菌生长和治疗细菌感染的方法，所述抗体为例如针对感染性疾病相关的靶标诸如膜糖蛋白受体(MSR1)、壁磷壁酸(WTA)或蛋白A特异性的抗体。